No Cover Image

Journal article 368 views 33 downloads

COVID-19 and pregnancy: A European study on pre- and post-infection medication use

Eimir Hurley Orcid Logo, Benjamin P. Geisler Orcid Logo, Angela Lupattelli Orcid Logo, Beatriz Poblador-Plou Orcid Logo, Régis Lassalle, Jérémy Jové, Marie-Agnes Bernard, Dunia Sakr, Gabriel Sanfélix-Gimeno Orcid Logo, Francisco Sánchez-Saez Orcid Logo, Clara L. Rodríguez-Bernal Orcid Logo, Mònica Sabaté Orcid Logo, Elena Ballarín Orcid Logo, Cristina Aguilera Orcid Logo, Sue Jordan Orcid Logo, Daniel Thayer, Ian Farr, Saira Ahmed, Claudia Bartolini Orcid Logo, Giorgio Limoncella, Olga Paoletti, Rosa Gini Orcid Logo, Luigi A. Maglanoc Orcid Logo, Elena Dudukina Orcid Logo, Vera Ehrenstein Orcid Logo, Ema Alsina, Tiago A. Vaz Orcid Logo, Judit Riera-Arnau Orcid Logo, Miriam C. J. M. Sturkenboom Orcid Logo, Hedvig M. E. Nordeng Orcid Logo

European Journal of Clinical Pharmacology, Volume: 80, Issue: 5, Pages: 707 - 716

Swansea University Author: Sue Jordan Orcid Logo

  • 65969.pdf

    PDF | Version of Record

    © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License.

    Download (2.16MB)

Check full text

DOI (Published version): 10.1007/s00228-024-03639-z

Abstract

PurposeThe COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location.MethodsWe conducted...

Full description

Published in: European Journal of Clinical Pharmacology
ISSN: 0031-6970 1432-1041
Published: Springer Science and Business Media LLC 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa65969
first_indexed 2024-04-04T15:49:46Z
last_indexed 2024-11-25T14:17:13Z
id cronfa65969
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2024-05-29T13:31:59.7876991</datestamp><bib-version>v2</bib-version><id>65969</id><entry>2024-04-04</entry><title>COVID-19 and pregnancy: A European study on pre- and post-infection medication use</title><swanseaauthors><author><sid>24ce9db29b4bde1af4e83b388aae0ea1</sid><ORCID>0000-0002-5691-2987</ORCID><firstname>Sue</firstname><surname>Jordan</surname><name>Sue Jordan</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-04-04</date><deptcode>HSOC</deptcode><abstract>PurposeThe COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location.MethodsWe conducted an observational study using six electronic healthcare databases from six European regions (Aragon/Spain; France; Norway; Tuscany, Italy; Valencia/Spain; and Wales/UK). The prevalence of primary care prescribing or dispensing was compared in the 30-day periods before and after a positive COVID-19 test or diagnosis.ResultsThe study included 294,126 pregnant women, of whom 8943 (3.0%) tested positive for, or were diagnosed with, COVID-19 during their pregnancy. A significantly higher use of antithrombotic medications was observed particularly after COVID-19 infection in the second and third trimesters. The highest increase was observed in the Valencia region where use of antithrombotic medications in the third trimester increased from 3.8% before COVID-19 to 61.9% after the infection. Increases in other countries were lower; for example, in Norway, the prevalence of antithrombotic medication use changed from around 1&#x2013;2% before to around 6% after COVID-19 in the third trimester. Smaller and less consistent increases were observed in the use of other drug classes, such as antimicrobials and systemic corticosteroids.ConclusionOur findings highlight the substantial impact of COVID-19 on primary care medication use among pregnant women, with a marked increase in the use of antithrombotic medications post-COVID-19. These results underscore the need for further research to understand the broader implications of these patterns on maternal and neonatal/fetal health outcomes.</abstract><type>Journal Article</type><journal>European Journal of Clinical Pharmacology</journal><volume>80</volume><journalNumber>5</journalNumber><paginationStart>707</paginationStart><paginationEnd>716</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0031-6970</issnPrint><issnElectronic>1432-1041</issnElectronic><keywords>COVID-19; Pregnancy; Drug utilization study; Antithrombotic medications; Anti-bacterial agents; Steroids; Antiviral agents</keywords><publishedDay>1</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-05-01</publishedDate><doi>10.1007/s00228-024-03639-z</doi><url/><notes/><college>COLLEGE NANME</college><department>Health and Social Care School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HSOC</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>Open access funding provided by University of Oslo (incl Oslo University Hospital) The project has received support from the European Medicines Agency under the Framework service contract no. EMA/2018/28/PE (Lot 4).</funders><projectreference/><lastEdited>2024-05-29T13:31:59.7876991</lastEdited><Created>2024-04-04T16:47:28.2849117</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">School of Health and Social Care - Nursing</level></path><authors><author><firstname>Eimir</firstname><surname>Hurley</surname><orcid>0000-0001-6776-1224</orcid><order>1</order></author><author><firstname>Benjamin P.</firstname><surname>Geisler</surname><orcid>0000-0003-1704-6067</orcid><order>2</order></author><author><firstname>Angela</firstname><surname>Lupattelli</surname><orcid>0000-0002-8787-3183</orcid><order>3</order></author><author><firstname>Beatriz</firstname><surname>Poblador-Plou</surname><orcid>0000-0002-5119-5093</orcid><order>4</order></author><author><firstname>R&#xE9;gis</firstname><surname>Lassalle</surname><order>5</order></author><author><firstname>J&#xE9;r&#xE9;my</firstname><surname>Jov&#xE9;</surname><order>6</order></author><author><firstname>Marie-Agnes</firstname><surname>Bernard</surname><order>7</order></author><author><firstname>Dunia</firstname><surname>Sakr</surname><order>8</order></author><author><firstname>Gabriel</firstname><surname>Sanf&#xE9;lix-Gimeno</surname><orcid>0000-0001-7098-4576</orcid><order>9</order></author><author><firstname>Francisco</firstname><surname>S&#xE1;nchez-Saez</surname><orcid>0000-0002-3011-9884</orcid><order>10</order></author><author><firstname>Clara L.</firstname><surname>Rodr&#xED;guez-Bernal</surname><orcid>0000-0003-2617-8635</orcid><order>11</order></author><author><firstname>M&#xF2;nica</firstname><surname>Sabat&#xE9;</surname><orcid>0000-0001-6206-1085</orcid><order>12</order></author><author><firstname>Elena</firstname><surname>Ballar&#xED;n</surname><orcid>0000-0001-9786-6617</orcid><order>13</order></author><author><firstname>Cristina</firstname><surname>Aguilera</surname><orcid>0000-0002-7985-7327</orcid><order>14</order></author><author><firstname>Sue</firstname><surname>Jordan</surname><orcid>0000-0002-5691-2987</orcid><order>15</order></author><author><firstname>Daniel</firstname><surname>Thayer</surname><order>16</order></author><author><firstname>Ian</firstname><surname>Farr</surname><order>17</order></author><author><firstname>Saira</firstname><surname>Ahmed</surname><order>18</order></author><author><firstname>Claudia</firstname><surname>Bartolini</surname><orcid>0000-0001-8630-4598</orcid><order>19</order></author><author><firstname>Giorgio</firstname><surname>Limoncella</surname><order>20</order></author><author><firstname>Olga</firstname><surname>Paoletti</surname><order>21</order></author><author><firstname>Rosa</firstname><surname>Gini</surname><orcid>0000-0002-6250-877x</orcid><order>22</order></author><author><firstname>Luigi A.</firstname><surname>Maglanoc</surname><orcid>0000-0003-2556-0779</orcid><order>23</order></author><author><firstname>Elena</firstname><surname>Dudukina</surname><orcid>0000-0002-4238-049x</orcid><order>24</order></author><author><firstname>Vera</firstname><surname>Ehrenstein</surname><orcid>0000-0002-3415-3254</orcid><order>25</order></author><author><firstname>Ema</firstname><surname>Alsina</surname><order>26</order></author><author><firstname>Tiago A.</firstname><surname>Vaz</surname><orcid>0000-0003-3125-0662</orcid><order>27</order></author><author><firstname>Judit</firstname><surname>Riera-Arnau</surname><orcid>0000-0001-7591-0218</orcid><order>28</order></author><author><firstname>Miriam C. J. M.</firstname><surname>Sturkenboom</surname><orcid>0000-0003-1360-2388</orcid><order>29</order></author><author><firstname>Hedvig M. E.</firstname><surname>Nordeng</surname><orcid>0000-0001-6361-2918</orcid><order>30</order></author></authors><documents><document><filename>65969__30203__5ec94054bbab4f24877d88dd353b64f3.pdf</filename><originalFilename>65969.pdf</originalFilename><uploaded>2024-05-01T12:08:09.2081251</uploaded><type>Output</type><contentLength>2265071</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2024-05-29T13:31:59.7876991 v2 65969 2024-04-04 COVID-19 and pregnancy: A European study on pre- and post-infection medication use 24ce9db29b4bde1af4e83b388aae0ea1 0000-0002-5691-2987 Sue Jordan Sue Jordan true false 2024-04-04 HSOC PurposeThe COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location.MethodsWe conducted an observational study using six electronic healthcare databases from six European regions (Aragon/Spain; France; Norway; Tuscany, Italy; Valencia/Spain; and Wales/UK). The prevalence of primary care prescribing or dispensing was compared in the 30-day periods before and after a positive COVID-19 test or diagnosis.ResultsThe study included 294,126 pregnant women, of whom 8943 (3.0%) tested positive for, or were diagnosed with, COVID-19 during their pregnancy. A significantly higher use of antithrombotic medications was observed particularly after COVID-19 infection in the second and third trimesters. The highest increase was observed in the Valencia region where use of antithrombotic medications in the third trimester increased from 3.8% before COVID-19 to 61.9% after the infection. Increases in other countries were lower; for example, in Norway, the prevalence of antithrombotic medication use changed from around 1–2% before to around 6% after COVID-19 in the third trimester. Smaller and less consistent increases were observed in the use of other drug classes, such as antimicrobials and systemic corticosteroids.ConclusionOur findings highlight the substantial impact of COVID-19 on primary care medication use among pregnant women, with a marked increase in the use of antithrombotic medications post-COVID-19. These results underscore the need for further research to understand the broader implications of these patterns on maternal and neonatal/fetal health outcomes. Journal Article European Journal of Clinical Pharmacology 80 5 707 716 Springer Science and Business Media LLC 0031-6970 1432-1041 COVID-19; Pregnancy; Drug utilization study; Antithrombotic medications; Anti-bacterial agents; Steroids; Antiviral agents 1 5 2024 2024-05-01 10.1007/s00228-024-03639-z COLLEGE NANME Health and Social Care School COLLEGE CODE HSOC Swansea University Another institution paid the OA fee Open access funding provided by University of Oslo (incl Oslo University Hospital) The project has received support from the European Medicines Agency under the Framework service contract no. EMA/2018/28/PE (Lot 4). 2024-05-29T13:31:59.7876991 2024-04-04T16:47:28.2849117 Faculty of Medicine, Health and Life Sciences School of Health and Social Care - Nursing Eimir Hurley 0000-0001-6776-1224 1 Benjamin P. Geisler 0000-0003-1704-6067 2 Angela Lupattelli 0000-0002-8787-3183 3 Beatriz Poblador-Plou 0000-0002-5119-5093 4 Régis Lassalle 5 Jérémy Jové 6 Marie-Agnes Bernard 7 Dunia Sakr 8 Gabriel Sanfélix-Gimeno 0000-0001-7098-4576 9 Francisco Sánchez-Saez 0000-0002-3011-9884 10 Clara L. Rodríguez-Bernal 0000-0003-2617-8635 11 Mònica Sabaté 0000-0001-6206-1085 12 Elena Ballarín 0000-0001-9786-6617 13 Cristina Aguilera 0000-0002-7985-7327 14 Sue Jordan 0000-0002-5691-2987 15 Daniel Thayer 16 Ian Farr 17 Saira Ahmed 18 Claudia Bartolini 0000-0001-8630-4598 19 Giorgio Limoncella 20 Olga Paoletti 21 Rosa Gini 0000-0002-6250-877x 22 Luigi A. Maglanoc 0000-0003-2556-0779 23 Elena Dudukina 0000-0002-4238-049x 24 Vera Ehrenstein 0000-0002-3415-3254 25 Ema Alsina 26 Tiago A. Vaz 0000-0003-3125-0662 27 Judit Riera-Arnau 0000-0001-7591-0218 28 Miriam C. J. M. Sturkenboom 0000-0003-1360-2388 29 Hedvig M. E. Nordeng 0000-0001-6361-2918 30 65969__30203__5ec94054bbab4f24877d88dd353b64f3.pdf 65969.pdf 2024-05-01T12:08:09.2081251 Output 2265071 application/pdf Version of Record true © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License. true eng https://creativecommons.org/licenses/by/4.0/
title COVID-19 and pregnancy: A European study on pre- and post-infection medication use
spellingShingle COVID-19 and pregnancy: A European study on pre- and post-infection medication use
Sue Jordan
title_short COVID-19 and pregnancy: A European study on pre- and post-infection medication use
title_full COVID-19 and pregnancy: A European study on pre- and post-infection medication use
title_fullStr COVID-19 and pregnancy: A European study on pre- and post-infection medication use
title_full_unstemmed COVID-19 and pregnancy: A European study on pre- and post-infection medication use
title_sort COVID-19 and pregnancy: A European study on pre- and post-infection medication use
author_id_str_mv 24ce9db29b4bde1af4e83b388aae0ea1
author_id_fullname_str_mv 24ce9db29b4bde1af4e83b388aae0ea1_***_Sue Jordan
author Sue Jordan
author2 Eimir Hurley
Benjamin P. Geisler
Angela Lupattelli
Beatriz Poblador-Plou
Régis Lassalle
Jérémy Jové
Marie-Agnes Bernard
Dunia Sakr
Gabriel Sanfélix-Gimeno
Francisco Sánchez-Saez
Clara L. Rodríguez-Bernal
Mònica Sabaté
Elena Ballarín
Cristina Aguilera
Sue Jordan
Daniel Thayer
Ian Farr
Saira Ahmed
Claudia Bartolini
Giorgio Limoncella
Olga Paoletti
Rosa Gini
Luigi A. Maglanoc
Elena Dudukina
Vera Ehrenstein
Ema Alsina
Tiago A. Vaz
Judit Riera-Arnau
Miriam C. J. M. Sturkenboom
Hedvig M. E. Nordeng
format Journal article
container_title European Journal of Clinical Pharmacology
container_volume 80
container_issue 5
container_start_page 707
publishDate 2024
institution Swansea University
issn 0031-6970
1432-1041
doi_str_mv 10.1007/s00228-024-03639-z
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str School of Health and Social Care - Nursing{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}School of Health and Social Care - Nursing
document_store_str 1
active_str 0
description PurposeThe COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location.MethodsWe conducted an observational study using six electronic healthcare databases from six European regions (Aragon/Spain; France; Norway; Tuscany, Italy; Valencia/Spain; and Wales/UK). The prevalence of primary care prescribing or dispensing was compared in the 30-day periods before and after a positive COVID-19 test or diagnosis.ResultsThe study included 294,126 pregnant women, of whom 8943 (3.0%) tested positive for, or were diagnosed with, COVID-19 during their pregnancy. A significantly higher use of antithrombotic medications was observed particularly after COVID-19 infection in the second and third trimesters. The highest increase was observed in the Valencia region where use of antithrombotic medications in the third trimester increased from 3.8% before COVID-19 to 61.9% after the infection. Increases in other countries were lower; for example, in Norway, the prevalence of antithrombotic medication use changed from around 1–2% before to around 6% after COVID-19 in the third trimester. Smaller and less consistent increases were observed in the use of other drug classes, such as antimicrobials and systemic corticosteroids.ConclusionOur findings highlight the substantial impact of COVID-19 on primary care medication use among pregnant women, with a marked increase in the use of antithrombotic medications post-COVID-19. These results underscore the need for further research to understand the broader implications of these patterns on maternal and neonatal/fetal health outcomes.
published_date 2024-05-01T08:13:51Z
_version_ 1829542436008886272
score 11.058203

Similar Items